Creative Planning
ABUS icon

Creative Planning’s Arbutus Biopharma ABUS Stock Holding History

Creative Planning’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298K Buy
62,111
+1,994
+3% +$8.76K ﹤0.01% 3566
2026
Q1 		$271K Buy
60,117
+8,200
+16% +$35.9K ﹤0.01% 3495
2025
Q4 		$250K Buy
51,917
+225
+0.4% +$1.01K ﹤0.01% 3374
2025
Q3 		$235K Sell
51,692
-1,246
-2% -$4.58K ﹤0.01% 3348
2025
Q2 		$164K Sell
52,938
-9,151
-15% -$30.4K ﹤0.01% 3302
2025
Q1 		$217K Buy
62,089
+13,745
+28% +$45.8K ﹤0.01% 2997
2024
Q4 		$158K Sell
48,344
-1,156
-2% -$4.25K ﹤0.01% 3046
2024
Q3 		$191K Buy
49,500
+5,989
+14% +$23K ﹤0.01% 2855
2024
Q2 		$134K Buy
43,511
+13,651
+46% +$41K ﹤0.01% 2780
2024
Q1 		$77K Buy
29,860
+15,294
+105% +$39.6K ﹤0.01% 2742
2023
Q4 		$36.4K Buy
+14,566
New +$28.5K ﹤0.01% 2667
2021
Q2 		– Sell
-24,210
Closed -$81K – 2057
2021
Q1 		$81K Sell
24,210
-2,493
-9% -$9.62K ﹤0.01% 2283
2020
Q4 		$95K Buy
+26,703
New +$93.5K ﹤0.01% 2036
2020
Q3 		– Sell
-32,748
Closed -$60K – 2141
2020
Q2 		$60K Buy
+32,748
New +$53.6K ﹤0.01% 1741
2017
Q3 		– Sell
-1,050
Closed -$4K – 1891
2017
Q2 		$4K Buy
1,050
+50
+5% +$172 ﹤0.01% 4065
2017
Q1 		$3K Sell
1,000
-500
-33% -$1.39K ﹤0.01% 4126
2016
Q4 		$4K Buy
1,500
+500
+50% +$1.46K ﹤0.01% 4030
2016
Q3 		$3K Hold
1,000
– – ﹤0.01% 4063
2016
Q2 		$3K Sell
1,000
-450
-31% -$1.91K ﹤0.01% 3849
2016
Q1 		$6K Sell
1,450
-50
-3% -$179 ﹤0.01% 3471
2015
Q4 		$7K Hold
1,500
– – ﹤0.01% 3481
2015
Q3 		$9K Sell
1,500
-11,000
-88% -$97.5K ﹤0.01% 3249
2015
Q2 		$148K Buy
12,500
+12,450
+24,900% +$189K ﹤0.01% 930
2015
Q1 		$1K Hold
50
– – ﹤0.01% 3993
2014
Q4 		$1K Sell
50
-500
-91% -$8.63K ﹤0.01% 3939
2014
Q3 		$12K Buy
+550
New +$8.98K ﹤0.01% 2830

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Creative Planning's ABUS Position: Q2 2026 in Review

Creative Planning increased its Arbutus Biopharma (ABUS) stake by 3.3% in Q2 2026, buying an estimated $8.76K and bringing the position to 62,111 shares worth $298K. The position accounts for ﹤0.01% of the portfolio, ranked #3566.

Creative Planning first reported a position in ABUS in Q3 2014 and has held it in 26 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Creative Planning held 62,111 shares of Arbutus Biopharma worth $298K as of Q2 2026.
  • Creative Planning bought 1,994 Arbutus Biopharma shares in Q2 2026, an estimated $8.76K.
  • Arbutus Biopharma made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3566 holding.
  • Creative Planning first reported a position in Arbutus Biopharma in Q3 2014 and has held it in 26 quarters since.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.